<?xml version="1.0" encoding="UTF-8"?>
<p>Clinical trials and real‐life experiences in regions such as North America and Europe demonstrate high rates of efficacy and low rates of treatment‐related adverse effects with DAA‐containing regimens.
 <xref rid="hep41482-bib-0003" ref-type="ref">3</xref>, 
 <xref rid="hep41482-bib-0004" ref-type="ref">4</xref>, 
 <xref rid="hep41482-bib-0005" ref-type="ref">5</xref>, 
 <xref rid="hep41482-bib-0006" ref-type="ref">6</xref>, 
 <xref rid="hep41482-bib-0007" ref-type="ref">7</xref> In clinical trials investigating ledipasvir (LDV)/sofosbuvir (SOF), grazoprevir/elbasvir, glecaprevir/pibrentasvir, or velpatasvir/SOF, sustained virologic response (SVR) rates are in excess of 95%, and treatment discontinuations due to adverse events are less than 1%, albeit in individuals carefully screened for clinical trials.
 <xref rid="hep41482-bib-0003" ref-type="ref">3</xref>, 
 <xref rid="hep41482-bib-0004" ref-type="ref">4</xref>, 
 <xref rid="hep41482-bib-0005" ref-type="ref">5</xref>, 
 <xref rid="hep41482-bib-0006" ref-type="ref">6</xref> This includes very low rates of clinically significant renal insufficiency, anemia, and transaminitis. These findings provide impetus for streamlining HCV treatment in order to scale up therapy in low‐income and low‐middle‐income countries (LMICs).
</p>
